Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care?

Pediatric Blood and Cancer

Volumn 45, Issue 3, 2005, Pages 244-247

  Ammann, Roland A ^a   Simon, Arne ^b   De Bont, Eveline S J M ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cancer; Children; Fever; Infections; Neutropenia; Supportive care

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ANTIBIOTIC THERAPY; BACTEREMIA; CHILDHOOD CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; MORTALITY; NOTE; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; EVIDENCE-BASED MEDICINE; FEVER; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 23044491450     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20287     Document Type: Note

References (20)

1. Alexander SW, Walsh TJ, Freifeld AG, et al. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2002. p 1239-1283.
2. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-1065.
3. Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002;39: 77-85.
4. Holdsworth M, Hanrahan J, Albanese B, et al. Outpatient management of febrile neutropenia in children with cancer. Paediatr Drugs 2003;5:443-455.
5. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311.
6. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International antimicrobial therapy cooperative group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-318.
7. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126-134.
8. Aquino VM, Herrera L, Sandler ES, et al. Feasibility of oral ciprofloxacin for the outpatient management, of febrile neutropenia in selected children with cancer. Cancer 2000;88:1710-1714.
9. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant, disease: A single-center, randomized, controlled trial in Argentina. Cancer 2003;97:1775-1780.
10. Oude Nijhuis CSM, W.A K, Daenen SM, et al. No antibiotics for selected febrile neutropenic cancer patients might be safe and feasible. Proc Am Soc Clin Oncol 2003;22:736 (Abstract 2961).
11. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
12. Vidal L, Paul M, Ben dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004;54:29-37.
13. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 1,100 pediatric oncology patients with fever and neutropenia. Cancer 2001;92:909-913.
14. Feld R, Paesmans M, Freifeld AG, et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002;35:1463-1468.
15. Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2003;22:1138-1142.
16. Mosteller F. Methods of technology assessment. In Committee for Evaluating Medical Technologies in Clinical Use, Institute of Medicine, editors. Assessing medical technologies. Washington: National Academy Press; 195. p 70-175.
17. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
18. Ammann RA, Hirt A, Ridolfi Luthy A, et al. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004;23:61-67.
19. Petrilli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial. Med Pediatr Oncol 2000;34: 87-91.
20. Ammann RA. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: A single-center, randomized, controlled trial in Argentina. Cancer 2004;100:1547 (Letter).